Literature DB >> 27027301

The Role of Antibiotics in Gut Microbiota Modulation: The Eubiotic Effects of Rifaximin.

Francesca Romana Ponziani1, Franco Scaldaferri, Valentina Petito, Francesco Paroni Sterbini, Silvia Pecere, Loris R Lopetuso, Alessandra Palladini, Viviana Gerardi, Luca Masucci, Maurizio Pompili, Giovanni Cammarota, Maurizio Sanguinetti, Antonio Gasbarrini.   

Abstract

Antibiotics are mainly used in clinical practice for their activity against pathogens, but they also alter the composition of commensal gut microbial community. Rifaximin is a non-absorbable antibiotic with additional effects on the gut microbiota about which very little is known. It is still not clear to what extent rifaximin can be able to modulate gut microbiota composition and diversity in different clinical settings. Studies based on culture-dependent techniques revealed that rifaximin treatment promotes the growth of beneficial bacteria, such as Bifidobacteria and Lactobacilli. Accordingly, our metagenomic analysis carried out on patients with different gastrointestinal and liver diseases highlighted a significant increase in Lactobacilli after rifaximin treatment, persisting in the short time period. This result was independent of the disease background and was not accompanied by a significant alteration of the overall gut microbial ecology. This suggests that rifaximin can exert important eubiotic effects independently of the original disease, producing a favorable gut microbiota perturbation without changing its overall composition and diversity.
© 2016 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27027301     DOI: 10.1159/000443361

Source DB:  PubMed          Journal:  Dig Dis        ISSN: 0257-2753            Impact factor:   2.404


  38 in total

1.  Rifaximin Re-treatment in Patients with Irritable Bowel Syndrome: Feels Like the First Time?

Authors:  Francesca Romana Ponziani; Maurizio Pompili; Antonio Gasbarrini
Journal:  Dig Dis Sci       Date:  2017-09       Impact factor: 3.199

Review 2.  Drug-Induced Small Bowel Injury: a Challenging and Often Forgotten Clinical Condition.

Authors:  Carmelo Scarpignato; Ingvar Bjarnason
Journal:  Curr Gastroenterol Rep       Date:  2019-11-13

3.  Rifaximin Protects against Malathion-Induced Rat Testicular Toxicity: A Possible Clue on Modulating Gut Microbiome and Inhibition of Oxidative Stress by Mitophagy.

Authors:  Nesreen Nabil Omar; Rasha A Mosbah; Wedad S Sarawi; Marwa Medhet Rashed; Amira M Badr
Journal:  Molecules       Date:  2022-06-24       Impact factor: 4.927

Review 4.  Modulation of gut microbiome in nonalcoholic fatty liver disease: pro-, pre-, syn-, and antibiotics.

Authors:  Min Seok Cho; Sang Yeol Kim; Ki Tae Suk; Byung-Yong Kim
Journal:  J Microbiol       Date:  2018-10-25       Impact factor: 3.422

5.  Effects of Rifaximin on Central Responses to Social Stress-a Pilot Experiment.

Authors:  Huiying Wang; Christoph Braun; Paul Enck
Journal:  Neurotherapeutics       Date:  2018-07       Impact factor: 7.620

6.  Strain-level analysis of gut-resident pro-inflammatory viridans group Streptococci suppressed by long-term cotrimoxazole prophylaxis among HIV-positive children in Zimbabwe.

Authors:  Ethan K Gough; Claire D Bourke; Chipo Berejena; Annie Shonhai; Mutsa Bwakura-Dangarembizi; Andrew J Prendergast; Amee R Manges
Journal:  Gut Microbes       Date:  2020-02-05

Review 7.  Guidelines for the prevention and treatment of travelers' diarrhea: a graded expert panel report.

Authors:  Mark S Riddle; Bradley A Connor; Nicholas J Beeching; Herbert L DuPont; Davidson H Hamer; Phyllis Kozarsky; Michael Libman; Robert Steffen; David Taylor; David R Tribble; Jordi Vila; Philipp Zanger; Charles D Ericsson
Journal:  J Travel Med       Date:  2017-04-01       Impact factor: 8.490

Review 8.  Modulation of the Microbiome in Parkinson's Disease: Diet, Drug, Stool Transplant, and Beyond.

Authors:  Ethan G Brown; Samuel M Goldman
Journal:  Neurotherapeutics       Date:  2020-10-09       Impact factor: 6.088

Review 9.  Eubiotic properties of rifaximin: Disruption of the traditional concepts in gut microbiota modulation.

Authors:  Francesca Romana Ponziani; Maria Assunta Zocco; Francesca D'Aversa; Maurizio Pompili; Antonio Gasbarrini
Journal:  World J Gastroenterol       Date:  2017-07-07       Impact factor: 5.742

Review 10.  A Review of Experimental and Off-Label Therapies for Clostridium difficile Infection.

Authors:  Csaba Fehér; Alex Soriano; Josep Mensa
Journal:  Infect Dis Ther       Date:  2016-12-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.